Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Nov 1;10(8):813-825.
doi: 10.2217/pme.13.89.

Bumps along the translational pathway: anticipating uptake of tailored smoking cessation treatment

Alexandra Elizabeth Shields  1 , Mehdi Najafzadeh  2 , Anna Boonin Schachter  3
Affiliations

Bumps along the translational pathway: anticipating uptake of tailored smoking cessation treatment

Alexandra Elizabeth Shields et al. Per Med. .

Abstract

Aim: To assess potential barriers to clinical integration of tailored smoking cessation treatment among African American and white smokers in the USA.

Methods: A total of 392 smokers (203 white and 189 African American) identified within a national random digit dial survey (response rate: 40.1%; 81.2% among households with whom we were able to make contact) of 1200 African Americans and 1200 white Americans. Respondents answered several closed-ended survey items addressing beliefs regarding what influences a smoker's ability to quit, past pharmacotherapy use, and their willingness to undergo genetic assessment in order to be matched to optimal treatment, among other items.

Results: In this first nationally representative survey of US smokers, 77% of respondents expressed willingness to undergo genetic testing in order to be matched to optimal pharmacotherapy, yet only 18% had ever used pharmacotherapy in a previous quit attempt. Smokers who rated 'medications and counseling' as very important in quitting were significantly more likely to endorse genetic testing (odds ratio [OR]: 8.94; 95% CI: 1.86-43.06), while those rating 'having God's help' as very important were significantly less likely to express willingness to undergo testing (OR: 0.11; 95% CI: 0.02-0.71). African American smokers were more likely than white smokers to express willingness to undergo genetic testing (OR: 3.80; 95% CI: 1.09-13.22), despite lower rates of previous pharmacotherapy use.

Conclusion: While smokers reported high rates of willingness to undergo genetic testing to be matched to optimal treatment, these results suggest that smokers' willingness to use medications indicated by genetic test results may prove a significant barrier to realizing the promise of tailored smoking cessation treatment. The role of spirituality in smokers' willingness to use medication is an area for further study.

Keywords: genetic testing; pharmacogenomic treatment for smoking; pharmacogenomics; pharmacotherapy; racial differences in pharmacotherapy use; smoking.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Similar articles

See all similar articles

Cited by

References

    1. Green ED, Guyer MS. Charting a course for genomic medicine from base pairs to bedside. Nature. 2011;470(7333):204–213. ▪ Details the vision for the future of genomics research and the path towards an era of genomic medicine

    1. Shields AE, Lerman C. Anticipating clinical integration of pharmacogenetic treatment strategies for addiction: are primary care physicians ready? Clin. Pharmacol. Ther. 2008;83(4):635–639. - PubMed
    1. CDC. Smoking-attributable mortality years of potential life lost, and productivity losses – United States, 2000–2004. MMWR Morb. Mortal. Wkly Rep. 2008;57(45):1226–1228. - PubMed
    1. Le Houezec J, Mcneill A, Britton J. Tobacco nicotine and harm reduction. Indian J. Public Health. 2011;30(2):119–123. - PubMed
    1. The Aspect Consortium. Tobacco or Health in the European Union. Past, Present and Future. European Communities, Luxembourg, Belgium. 2004

Website

    1. SAS Institute Inc. SAS/STAT(R) 9.2. User’s guide, second edition. PROC SURVEYLOGISTIC statementy. 2013 http://support.sas.com/documentation/cdl/en/statug/63033/HTML/default/vi....

LinkOut - more resources